Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vonoprazan - Takeda

Next Previous
Drug Profile

Vonoprazan - Takeda

Alternative Names: Lupivon; TAK-438; TAKECAB; VOCINTI; Vocinti; VONOPION®; Vonoprazan fumarate; VONOSAP®; VOQUEZNA; VOQUEZNA DUAL PAK; VOQUEZNA TRIPLE PAK

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer Phathom Pharmaceuticals; Takeda
  • Class Amines; Anti-inflammatories; Antibacterials; Antiulcers; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Reflux oesophagitis
  • Phase III Gastrointestinal disorders

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux(In adolescents) in USA (PO, Tablet)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Gastrointestinal-disorders(In volunteers) in USA (PO, Pellet)
  • 01 May 2025 Phathom paused planned phase II pHalcon-EoE-201 trial for Eosinophilic esophagitis (In adults, In adolescents) (PO, Tablet) due to cost optimization strategy (NCT06851559)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top